Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR) & Evidence Synthesis (ES)

Axtria has been a true strategic partner in the Real-World Evidence (RWE) journey. Axtria's long-term COE model, with a dedicated methodologist lead, onshore and offshore RWD programmers, data scientists, and medical writers, was instrumental in advancing the enterprise RWE strategy. Axtria's expertise enabled rapid label expansions, influenced clinical guidelines, and completed over 18 studies in just 24 months.

• A top 10 pharma company

Axtria played a critical role in expanding access to a CD3-directed mAB therapy for Stage 2 Type 1 Diabetes patients by deploying a predictive modeling solution that combined traditional machine learning with a deep neural BERT model. Axtria enabled the identification of asymptomatic individuals at high risk of disease progression. The initiative resulted in a 350% increase in patient identification, optimized screening efforts, and significantly expanded the therapy’s market reach.

• A top 15 pharma company

Axtria helped develop a scalable, AI-powered coaching solution for diabetes management. Built on Retrieval-Augmented Generation (RAG) and aligned with ADA guidelines, the GenAI coach provided personalized support through platforms such as WhatsApp and Line. The solution improved glycemic control, reduced provider workload, and enhanced patient engagement.

• A top 10 pharmaceutical company

Axtria collaborated during the pre-launch phase of a preventative therapy to build a compelling evidence base for payers and regulators. By combining systematic literature review, real-world evidence analysis, and economic modeling, Axtria helped identify key patient segments, quantify disease burden, and demonstrate economic value, accelerating market readiness and supporting successful launch and reimbursement discussions.

• Pharma company

Axtria engaged in a long-term COE model to advance the RWE strategy with a dedicated team of methodologists, RWD programmers, data scientists, and medical writers. Axtria supported over 20 studies that led to publications, regulatory submissions, and conference presentations. Flexible RWD simulations and real-world analytics enabled label expansion, clinical guideline updates, and economic models for payer engagement, strengthening scientific credibility and market positioning across therapeutic areas.

• A leading pharmaceutical company